PROphylaxis for paTiEnts at risk of COVID-19 infecTion (PROTECT-V).

Toby J L Humphrey, Davinder Dosanjh, Thomas F Hiemstra, Alex Richter, Michael Chen-Xu, Wendi Qian, Vivekanand Jha, Katrina Gatley, Rakshya Adhikari, Francis Dowling, Rona M Smith

OAI: oai:www.repository.cam.ac.uk:1810/348650 • DOI: 10.17863/CAM.96077

Background

Despite the introduction of vaccination, there remains a need for pre-exposure prophylactic agents against SARS-CoV-2. Several patient groups are more vulnerable to SARS-CoV-2 infection by virtue of underlying health conditions, treatments received or suboptimal responses to vaccination.

Methods

PROTECT-V is a platform trial testing pre-exposure prophylactic interventions against SARS-CoV-2 infection in vulnerable patient populations (organ transplant recipients; individuals with oncological/haematological diagnoses, immune deficiency or autoimmune diseases requiring immunosuppression or on dialysis). Multiple agents can be evaluated across multiple vulnerable populations sharing placebo groups, with the option of adding additional treatments at later time points as these become available. The primary endpoint is symptomatic SARS-CoV-2 infection, and each agent will be independently evaluated in real time when the required number of events occurs. Presently, three agents are approved in the platform: intranasal niclosamide, nasal and inhaled ciclesonide and intravenous sotrovimab.

Discussion

Despite the introduction of vaccination, there remains a need for pre-exposure prophylactic agents against SARS-CoV-2. Several patient groups are more vulnerable to COVID-19 disease by virtue of underlying health conditions, treatments received or suboptimal responses to vaccination.

Trial registration

ClinicalTrials.gov NCT04870333. EudraCT 2020-004144-28.

Platform trial prophylaxis Niclosamide Ciclesonide covid-19 SARS-CoV-2 Sotrovimab Humans covid-19 SARS-CoV-2